What is HC Wainwright's Forecast for Merus FY2027 Earnings?

Key Points

• HC Wainwright has revised its FY2027 EPS estimate for Merus to ($4.13) per share, indicating a slight improvement from the previous forecast of ($4.19).
• Currently, Merus has a market capitalization of $7.12 billion and maintains a "Neutral" rating with a price objective of $97.00 from HC Wainwright.
• Recent trading activity shows that institutional investors own 96.14% of Merus stock, with Wellington Management Group LLP increasing its position by 34.9%.

Merus N.V. (NASDAQ:MRUS - Free Report) - Equities research analysts at HC Wainwright raised their FY2027 EPS estimates for Merus in a research note issued on Monday, September 29th. HC Wainwright analyst A. Maldonado now anticipates that the biotechnology company will post earnings of ($4.13) per share for the year, up from their previous forecast of ($4.19). HC Wainwright has a "Neutral" rating and a $97.00 price objective on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus' FY2028 earnings at ($2.27) EPS and FY2029 earnings at $0.35 EPS.

Other equities analysts also recently issued reports about the company. Needham & Company LLC downgraded Merus from a "buy" rating to a "hold" rating and set a $96.00 price objective on the stock. in a research report on Monday. Guggenheim reissued a "neutral" rating and issued a $97.00 price target (down from $109.00) on shares of Merus in a report on Tuesday. William Blair downgraded Merus from a "strong-buy" rating to a "hold" rating in a research note on Monday. Lifesci Capital reiterated a "market perform" rating and set a $97.00 price objective on shares of Merus in a research report on Tuesday. Finally, Barclays restated an "equal weight" rating and set a $97.00 target price (down previously from $112.00) on shares of Merus in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $92.88.

Merus Stock Performance

Shares of Merus stock opened at $94.15 on Thursday. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $94.56. The company has a market capitalization of $7.12 billion, a P/E ratio of -17.12 and a beta of 1.26. The company has a fifty day moving average of $68.37 and a 200 day moving average of $55.38.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.The firm had revenue of $8.83 million during the quarter, compared to analysts' expectations of $9.77 million.

Institutional Trading of Merus

A number of institutional investors have recently bought and sold shares of MRUS. Wellington Management Group LLP increased its position in Merus by 34.9% during the first quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after acquiring an additional 1,220,519 shares during the last quarter. Paradigm Biocapital Advisors LP grew its holdings in Merus by 99.4% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after purchasing an additional 1,679,777 shares during the last quarter. Holocene Advisors LP grew its holdings in Merus by 18.8% during the 2nd quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company's stock valued at $117,048,000 after purchasing an additional 351,616 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Merus by 36.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company's stock worth $107,430,000 after purchasing an additional 541,168 shares during the period. Finally, Federated Hermes Inc. lifted its stake in Merus by 46.3% in the second quarter. Federated Hermes Inc. now owns 1,528,587 shares of the biotechnology company's stock worth $80,404,000 after purchasing an additional 483,962 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Peter B. Silverman sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 48,500 shares of company stock valued at $2,792,500. 3.70% of the stock is owned by company insiders.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.